Korea is a strategic key R&D site for Boehringer Ingelheim
By Whang, byung-woo | translator Alice Kang
25.04.01 05:28:30
가나다라
0
Boehringer Ingelheim Korea establishes new BD&L team, accelerates the Introduction of innovative new drugs
Aims to launch 20 new drugs and indications globally, including in Korea, within the next 7 years
Mentions Korea’s limited access to innovative new drugs... “At least one year behind other countries”
Boehringer Ingelheim, which has proposed integrated management of cardiovascular-kidney-metabolic syndrome (CRM) with Jardiance at the forefront, has been drawing on innovation through research and development (R&D) investment.
Boehringer Ingelheim has already invested more than EUR 5 billion (KRW 7.9666 trillion) in R&D in 2022 globally and has been steadily increasing its R&D ratio, with a 14.2% increase to EUR 5.8 billion (KRW 9.2412 trillion) in 2023.
In particular, the company has been continuing to forge active partnerships with the establishment of a new Business Development & Licensing (BD&L) department in Korea.
▲Ana-Maria Boie, General Manager and Head of Human Pharma at Boehringer Ingelheim Korea
Daily Pharm met with Ana-Maria Boie, General Manag
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)